carcinoma

(redirected from Merkel cell carcinoma)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

carcinoma:

see neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.
.

carcinoma

[‚kärs·ən′ō·mə]
(medicine)
A malignant epithelial tumor.

carcinoma

Pathol
1. any malignant tumour derived from epithelial tissue
2. another name for cancer
References in periodicals archive ?
Merkel cell carcinoma. Ann Oncol 2010; 21(Suppl 7):81- 85.
Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?.
Andres, "Histological, immunohistological, and clinical features of merkel cell carcinoma in correlation to merkel cell polyomavirus status," Journal of Skin Cancer, vol.
Merkel cell carcinoma has been rarely reported in association with hereditary cancer syndromes; however, the association and mechanism is still not clear.
Merkel cell carcinoma: prognosis and treatment of patients from a single institution.
Overview of Merkel cell carcinoma and recent advances in research.
Arnold, "Thoracic spinal metastasis of Merkel cell carcinoma in an immunocompromised patient: case report," Evidence-Based Spine-Care Journal, vol.
Few but significant data are available about the role of [sup.68]Ga-labeled SST-analogues PET/CT in Merkel cell carcinoma. [sup.68]Ga-labeled SST-analogues PET/CT is useful to stage and restage patients, and also to select treatment for PRRT and to assess treatment response.
A multicenter French study involving 89 patients with histologically confirmed Merkel cell carcinoma indicates that individuals with this rare and often aggressive neuroendocrine skin malignancy have an increased prevalence of vitamin D deficiency.
Washington, Nov 1 ( ANI ): A routine blood test may help predict survival in patients diagnosed with Merkel cell carcinoma, a deadly and aggressive form of skin cancer, according to new findings by Fox Chase Cancer Center researchers.
OncoSec's electroporation device, the OncoSec Medical System, now is being used in three ongoing clinical trials to treat metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.The device also has been used in Europe in Phase IV clinical trials to treat head and neck cancer and cutaneous and subcutaneous skin cancers.